Muscle relaxants

I. Introduction

Muscle relaxants are a diverse group of drugs that act on the central nervous system (CNS) or directly on skeletal muscle to reduce muscle tone, relieve muscle spasms, or produce muscle paralysis. They are commonly used in the treatment of musculoskeletal disorders, spasticity associated with neurological conditions, and as adjuncts in anesthesia during surgery. Based on their mechanism and site of action, they are classified into two major categories:

1. Centrally acting muscle relaxants – These drugs act primarily within the brain or spinal cord to reduce muscle tone.

2. Peripherally acting muscle relaxants (neuromuscular blocking agents) – These work at the neuromuscular junction and are used primarily during surgical procedures to induce muscle paralysis.

This classification is essential as it delineates therapeutic indications, routes of administration, duration of effect, and safety considerations.

---

II. Classification of Muscle Relaxants

A. Centrally Acting Muscle Relaxants

These drugs are commonly used to treat acute musculoskeletal pain or spasticity due to upper motor neuron syndromes. They do not directly affect skeletal muscle but instead modulate CNS pathways involved in muscle tone.

1. Antispasmodics (used for musculoskeletal pain):

• Cyclobenzaprine

• Methocarbamol

• Carisoprodol

• Metaxalone

• Chlorzoxazone

• Orphenadrine

2. Antispastics (used for neurological spasticity):

• Baclofen

• Tizanidine

• Diazepam

3. Dual-action agents:

• Diazepam (benzodiazepine with both antispasmodic and antispastic effects)

B. Peripherally Acting Muscle Relaxants

1. Non-depolarizing Neuromuscular Blockers (competitive antagonists of acetylcholine):

• Rocuronium

• Vecuronium

• Atracurium

• Cisatracurium

• Pancuronium

2. Depolarizing Neuromuscular Blockers:

• Succinylcholine

These agents are used exclusively in anesthetic practice to facilitate tracheal intubation or muscle relaxation during surgery or mechanical ventilation.

---

III. Mechanisms of Action

A. Centrally Acting Agents

These agents work through various mechanisms in the CNS:

• Cyclobenzaprine: Tricyclic structure, works at the brainstem to inhibit descending serotonergic pathways.

• Tizanidine: Alpha-2 adrenergic agonist that inhibits presynaptic motor neuron firing in the spinal cord.

• Baclofen: GABA_B receptor agonist that reduces excitatory neurotransmitter release in spinal cord motor neurons.

• Diazepam: GABA_A receptor potentiation leading to inhibitory neurotransmission.

• Methocarbamol, Metaxalone, Carisoprodol: Mechanisms not well defined but are believed to exert sedative and muscle-relaxant effects through CNS depression.

B. Peripherally Acting Agents

• Non-depolarizing agents: Block acetylcholine from binding to nicotinic receptors at the neuromuscular junction, preventing depolarization and contraction.

• Succinylcholine: Mimics acetylcholine, causing persistent depolarization and flaccid paralysis. Not reversed by acetylcholinesterase inhibitors.

---

IV. Indications and Uses

A. Therapeutic Indications of Centrally Acting Muscle Relaxants

1. Acute low back pain

2. Neck pain or cervical strain

3. Fibromyalgia (adjunct)

4. Spinal cord injury-related spasticity

5. Multiple sclerosis

6. Cerebral palsy

7. Stroke-related muscle spasticity

B. Therapeutic Indications of Peripherally Acting Agents

1. Facilitation of tracheal intubation

2. Surgical muscle relaxation

3. Control of ventilation (ICU settings)

4. Electroconvulsive therapy (to reduce injury)

5. Tetanus or status epilepticus (as part of ICU care)

---

V. Dosage and Administration

• Cyclobenzaprine: 5–10 mg orally up to three times daily; limit use to 2–3 weeks.

• Methocarbamol: 1500–4000 mg/day in divided doses.

• Baclofen: 5–20 mg orally TID; titrate slowly; intrathecal infusion in severe cases.

• Tizanidine: 2–4 mg orally up to three times daily.

• Rocuronium (IV): 0.6–1.2 mg/kg bolus; duration 30–70 minutes.

• Succinylcholine (IV): 1–1.5 mg/kg; rapid onset, short duration (~5–10 minutes).

---

VI. Adverse Effects

A. Centrally Acting Muscle Relaxants

Adverse Effects	Common Agents
Drowsiness, sedation	All centrally acting agents
Dizziness, confusion	Cyclobenzaprine, Diazepam
Dry mouth	Tizanidine
Hypotension	Tizanidine
Muscle weakness	Baclofen, Diazepam
Dependence, withdrawal	Carisoprodol, Diazepam
Liver enzyme elevation	Metaxalone, Chlorzoxazone

B. Peripherally Acting Muscle Relaxants

Adverse Effects	Common Agents
Respiratory paralysis	All neuromuscular blockers
Histamine release	Atracurium (flushing, hypotension)
Prolonged paralysis	Rocuronium, Pancuronium
Hyperkalemia	Succinylcholine
Malignant hyperthermia	Succinylcholine

VII. Contraindications

• Acute porphyria: Contraindicated for many centrally acting relaxants.

• Myasthenia gravis: Avoid non-depolarizing blockers.

• Severe hepatic impairment: Use caution with chlorzoxazone, metaxalone.

• Glaucoma, urinary retention, arrhythmias: Avoid cyclobenzaprine.

• Succinylcholine: Avoid in patients with burns, neuromuscular diseases, or trauma (due to hyperkalemia risk).

---

VIII. Drug Interactions

Drug/Class	Interaction
CNS depressants	Additive sedation (e.g., opioids, alcohol)
Antihypertensives	Exaggerated hypotensive effects
MAO inhibitors	Avoid with cyclobenzaprine (risk of serotonin syndrome)
CYP1A2 inhibitors	Tizanidine toxicity (e.g., ciprofloxacin)
Cholinesterase inhibitors	Reverse non-depolarizing NM blockers

IX. Monitoring Parameters

• Sedation level and CNS function

• Muscle strength and tone

• Liver function tests (for metaxalone, chlorzoxazone)

• Blood pressure and heart rate (especially with tizanidine)

• Respiratory function (for neuromuscular blockers)

---

X. Tolerance and Dependence

• Carisoprodol: Metabolized to meprobamate, associated with abuse and dependency.

• Diazepam: Tolerance, dependence, withdrawal risk—schedule IV.

• Short-term use is preferred for most skeletal muscle relaxants to avoid dependency.

---

XI. Special Populations

• Elderly: More sensitive to sedative and hypotensive effects. Avoid or use low doses.

• Pediatrics: Limited data; baclofen and diazepam sometimes used in children with spasticity.

• Pregnancy: Most are Category C; avoid unless benefit outweighs risk.

---

XII. Non-Pharmacological Alternatives

1. Physical therapy

2. Heat/cold therapy

3. Massage

4. TENS (Transcutaneous Electrical Nerve Stimulation)

5. Cognitive-behavioral therapy (CBT) for chronic pain

6. Yoga and stretching programs

---

XIII. Overdose and Toxicity

• CNS depression: Leading symptom in overdose

• Respiratory depression: Especially with benzodiazepines

• Coma or death: High doses or combined with alcohol/CNS depressants

• Succinylcholine: Risk of prolonged apnea, hyperkalemia, and malignant hyperthermia

Management includes supportive care, airway protection, and, if indicated, flumazenil for benzodiazepine overdose or dantrolene for malignant hyperthermia.

---

XIV. Drug Names and Brand Examples

Generic Name	Brand Names
Cyclobenzaprine	Flexeril, Amrix
Baclofen	Lioresal, Gablofen
Tizanidine	Zanaflex
Methocarbamol	Robaxin
Metaxalone	Skelaxin
Carisoprodol	Soma
Diazepam	Valium
Rocuronium	Zemuron
Vecuronium	Norcuron
Succinylcholine	Anectine, Quelicin